Timolumab clinical trials
Also written BTT1023.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses timolumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BTT1023
- 3
Studies by the year they started
3 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Studies
Open first, then newest update. How each study uses timolumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Trial of BTT1023 in Patients With Primary Sclerosing CholangitisCompletedPhase 2University of BirminghamNCT02239211Written as BTT1023
- BTT-1023 in Rheumatoid ArthritisCompletedPhase 1Biotie Therapies Corp.NCT00851240Written as BTT-1023
- BTT1023 in PsoriasisCompletedPhase 1Biotie Therapies Corp.NCT00871598Written as BTT1023
Codes
What other systems call timolumab · ClinicalTrials.gg INT000945
- MeSH (NLM) C000627434timolumabOne source NLM
- UNII (FDA) UJO03RO3K6TIMOLUMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627434 | timolumab | One source NLM |
| UNII (FDA) | UJO03RO3K6 | TIMOLUMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.